Buzhong Yiqitang Regulates Endoplasmic Reticulum Stress to Attenuate Cisplatin Resistance in Non-small Cell Lung Cancer via Nrf2/ROS Pathway
10.13422/j.cnki.syfjx.20250121
- VernacularTitle:基于Nrf2/ROS通路探讨补中益气汤调控内质网应激改善非小细胞肺癌的顺铂耐药性
- Author:
Dan YU
1
;
Qirui MU
1
;
He LI
1
;
Yuetong LIU
1
;
Jingyi HUANG
1
;
Yuan GAO
1
Author Information
1. College of Integrated Chinese and Western Medicine， Liaoning University of Traditional Chinese Medicine， Shenyang 110847， China
- Publication Type:Journal Article
- Keywords:
Buzhong Yiqitang;
non-small cell lung cancer;
nuclear factor E2-related factor 2（Nrf2）/reactive oxygen species（ROS）;
endoplasmic reticulum stress;
cisplatin resistance
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2025;31(10):98-104
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo investigate the mechanism of Buzhong Yiqitang in attenuating cisplatin resistance in non-small cell lung cancer by observing the effects of Buzhong Yiqitang on endoplasmic reticulum stress-related molecules in human lung adenocarcinoma cells （A549） and cisplatin-resistant cells in human lung adenocarcinoma cells （A549/DDP） via the nuclear factor E2-related factor 2（Nrf2）/reactive oxygen species（ROS） pathway. MethodsThe serum containing Buzhong Yiqitang was prepared and A549 cells and A549/DDP cells were cultured. The cells were randomized into groups A （A549 cells+blank serum）， B （A549 cells+20 mg·L-1 cisplatin+blank serum）， C （A549 cells+20 mg·L-1 cisplatin+10% Buzhong Yiqitang-containing serum）， D （A549/DDP cells+blank serum）， E （A549/DDP cells+20 mg·L-1 cisplatin+blank serum）， and F （A549/DDP cells+20 mg·L-1 cisplatin+10% Buzhong Yiqitang-containing serum）. The cell counting kit-8 （CCK-8） method was used to detect the half maximal inhibitory concentration （IC50） of cisplatin. The protein levels of Nrf2 and p-Nrf2 were determined by Western blotting. The DCFH-DA fluorescent probe was used to measure the content of reactive oxygen species （ROS） in each group. The protein levels of glucose-regulated protein 78 （GRP78）， activated transcription factor 6 （ATF6）， and C/EBP-homologous protein （CHOP） were determined by Western blot. ResultsCompared with group B， group C showed a reduction in IC50 of cisplatin （P<0.05）， which held true in group E compared with group F （P<0.05）. Moreover， the IC50 of cisplatin to A549/DDP cells was higher than that to A549 cells before and after Buzhong Yiqitang intervention （P<0.05）. Compared with group A， group B showed up-regulated protein levels of Nrf2 and p-Nrf2 （P<0.05）. Compared with group B， group C showed down-regulated protein levels of Nrf2 and p-Nrf2 （P<0.05）. Compared with group D， group E showed up-regulated protein levels of Nrf2 and p-Nrf2 （P<0.05）， which， however， were significantly down-regulated in group F （P<0.05）. The ROS content and the protein levels of GRP78， ATF6， and CHOP followed a descending trend of group C > group B > group A in A549 cells and group F > group E > group D in A549/DDP cells （P<0.05）. Moreover， the ROS content and the protein levels of GRP78， ATF6， and CHOP in A549 cells were higher than those in A549/DDP cells before and after Buzhong Yiqitang intervention （P<0.05）. ConclusionBuzhong Yiqitang may regulate endoplasmic reticulum stress via the Nrf2/ROS pathway to attenuate cisplatin resistance in non-small cell lung cancer.
